Sutro Biopharma, Inc.
Headquarters country
United States
Registry sponsor category
Industry
- Other names
- Sutro Biopharma, Inc.
- Company name
- Sutro Biopharma, Inc.
- Organisation type
- Industry
- Registered legal name
- Sutro Biopharma, Inc.
- US industry code (SIC)
- Biological products, (no disgnostic substances)
- Registry sponsor category
- Industry
- Website
- http://www.sutrobio.com
- SEC filer number (CIK)
- 0001382101
- Legal Entity Identifier (LEI)
- 5493005U6P15VD25P851
- Wikidata ID
- Q17143062
Related records
Trials (8)
- A Study of STRO-002 in Chinese Adults With Epithelial Ovarian Cancer and Other Advanced Malignant Solid Tumors
- A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer
- A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
- Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age With Relapsed/Refractory CBFA2T3::GLIS2 AML
- REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1
- Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies
- Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers
- Study to Investigate Luveltamab Tazevibulin in Adults With Advanced or Metastatic Non-small Cell Lung Cancer